RecruitingNot Applicable

The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients

China1,875 participantsStarted 2018-08-01

Plain-language summary

The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient age ≥18 years;
✓. Acute ischemic stroke patient confirmed by imaging;
✓. Time of onset: within 3 months;
✓. Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke;
✓. Baseline SWI sequence must have at least one CMB ;
✓. NIHSS≤10

Exclusion criteria

✕. MRI contraindication;
✕. Hemorrhagic transformation after acute Ischemic stroke;
✕. Contraindication for antiplatelet or anticoagulation therapy;
✕. Severe head trauma or intracranial hemorrhage occurred in the past six months;
✕. obvious coagulopathy;
✕. Other intracranial lesions associated with (such as tumor, cerebral vascular malformation);
✕. other unqualified patients judged by the investigator

What they're measuring

all cerebral bleeding events

Timeframe: 360 days

Trial details

NCT IDNCT03571763

SponsorGeneral Hospital of Shenyang Military Region

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-30

Contact for this trial

chen huisheng, doctor

86-24-28897511 chszh@aliyun.com

View on ClinicalTrials.gov More Ischemic Stroke trials